Product Name: CYP8A1 Antibody
Species Reactivity: Human, Mouse
Tested Applications: IHC-P, WB
Applications: For WB starting dilution is: 1:1000For IHC-P starting dilution is: 1:10~50
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 57 kDa
Immunogen: This CYP8A1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 30-61 amino acids from the N-terminal region of human CYP8A1.
Host Species: Rabbit
Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Physical State: Liquid
CAS NO.: 132869-83-1
Product: HOE-S 785026
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 2 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Prostacyclin synthase, Prostaglandin I2 synthase, PTGIS, CYP8, CYP8A1
Accession NO.: Q16647
Protein Ino: 2493373
Official Symbol: PTGIS
Geneid: 5740
Background: CYP8A1 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. However, this protein is considered a member of the cytochrome P450 superfamily on the basis of sequence similarity rather than functional similarity. This endoplasmic reticulum membrane protein catalyzes the conversion of prostglandin H2 to prostacyclin (prostaglandin I2), a potent vasodilator and inhibitor of platelet aggregation. An imbalance of prostacyclin and its physiological antagonist thromboxane A2 contribute to the development of myocardial infarction, stroke, and atherosclerosis.
PubMed ID:http://aac.asm.org/content/37/11/2459.abstract
